Kangmei Pharmaceutical revamps governance, streamlines oversight

Kangmei Pharmaceutical has approved extensive revisions to its corporate governance framework, including the cancellation of its Supervisory Board, effective December 10, 2025. The duties of the Supervisory Board will now be exercised by the board of directors' audit committee. This decision, along with amendments to the company’s articles of association and various internal regulations, will be submitted for shareholder approval.

The company has also revised its information disclosure affairs management system and established a new independent director, Ms. Yu Ying, following the resignation of Mr. Luo Tao. These changes aim to enhance compliance, improve investor relations, and ensure transparent and efficient management of internal information, including major events and related-party transactions.

Furthermore, Kangmei Pharmaceutical has updated its fundraising management system and the external guarantee management system, reinforcing stricter controls over the use of raised funds and the provision of external guarantees to protect investor interests. These comprehensive updates reflect the company's commitment to strengthening its corporate governance in line with regulatory requirements.